These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 2461003)

  • 1. Biologic response modifiers in gynecologic malignancies.
    Dutcher JP; Wadler S; Wiernik PH
    Yale J Biol Med; 1988; 61(4):367-78. PubMed ID: 2461003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biological response modifiers in renal cancer.
    Ackermann R
    Prog Clin Biol Res; 1988; 269():313-28. PubMed ID: 2455907
    [No Abstract]   [Full Text] [Related]  

  • 3. Cancer therapy by biological response modifiers.
    Herberman RB
    Clin Physiol Biochem; 1987; 5(3-4):238-48. PubMed ID: 2441918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biologicals and biological response modifiers: fourth modality of cancer treatment.
    Oldham RK
    Cancer Treat Rep; 1984 Jan; 68(1):221-32. PubMed ID: 6198081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adoptive cellular immunotherapy of human ovarian carcinoma xenografts in nude mice.
    Ortaldo JR; Porter HR; Miller P; Stevenson HC; Ozols RF; Hamilton TC
    Cancer Res; 1986 Sep; 46(9):4414-9. PubMed ID: 3089592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lymphocytes infiltrating ovarian carcinoma: modulation of functional activity by intraperitoneal treatment with biological response modifiers.
    Allavena P; Peri G; Di Bello M; Peccatori F; Chiaffarino F; Pirovano P; Mantovani A
    Nat Immun Cell Growth Regul; 1988; 7(4):230-8. PubMed ID: 3070372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gynecologic malignancies.
    Schilder RJ; Scher RM; Young RC
    Cancer Chemother Biol Response Modif; 1993; 14():530-56. PubMed ID: 8312118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy for gynecologic malignancies.
    Cohen CJ; Deppe G
    Prog Clin Biol Res; 1981; 70():371-4. PubMed ID: 7031696
    [No Abstract]   [Full Text] [Related]  

  • 9. Biologic therapy of melanoma with cytokines and lymphocytes.
    Bear HD; Hamad GG; Kostuchenko PJ
    Semin Surg Oncol; 1996; 12(6):436-45. PubMed ID: 8914208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Antitumoral action of interferons and interleukins in combination with radiotherapy. Part I: immunologic basis].
    Herskind C; Fleckenstein K; Lohr J; Li CY; Wenz F; Lohr F
    Strahlenther Onkol; 2004 Apr; 180(4):187-93. PubMed ID: 15057428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biological Response Modifiers Programme and cancer chemotherapy.
    Oldham RK
    Int J Tissue React; 1982; 4(3):173-88. PubMed ID: 6183193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Monoclonal anti-idiotype antibodies in immunotherapy of ovarian carcinoma (MAb ACA125) and breast carcinoma (MAb ACA14C5)].
    Wagner U; Köhler S; Prietl G; Giffels P; Schmidt-Nicolai S; Schlebusch H; Grünn U; Bender H; Biersack HJ; De Potter C; Krebs D; Wallwiener D
    Zentralbl Gynakol; 1999; 121(4):190-5. PubMed ID: 10355096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Laboratory correlates of adoptive immunotherapy with recombinant interleukin-2 and lymphokine-activated killer cells in humans.
    Boldt DH; Mills BJ; Gemlo BT; Holden H; Mier J; Paietta E; McMannis JD; Escobedo LV; Sniecinski I; Rayner AA
    Cancer Res; 1988 Aug; 48(15):4409-16. PubMed ID: 3260537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The immunobiology and immunotherapy of ovarian cancer.
    Bookman MA; Bast RC
    Semin Oncol; 1991 Jun; 18(3):270-91. PubMed ID: 1710393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Local conditions in the host influence immunotherapy with interleukin-2 and LAK cells.
    Steller EP; Ottow RT; Eggermont AM; Marquet RL; Sugarbaker PH
    Cancer Detect Prev; 1988; 12(1-6):81-90. PubMed ID: 3263202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gynecological malignancies.
    Schaebler DL; Schilder RJ; Young RC
    Cancer Chemother Biol Response Modif; 1996; 16():564-91. PubMed ID: 8639401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intraperitoneal recombinant alpha-interferon for "salvage" immunotherapy in stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study.
    Berek JS; Hacker NF; Lichtenstein A; Jung T; Spina C; Knox RM; Brady J; Greene T; Ettinger LM; Lagasse LD
    Cancer Res; 1985 Sep; 45(9):4447-53. PubMed ID: 4028027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biological response modifiers for the therapy of cancer.
    Herberman RB
    Ann Allergy; 1985 May; 54(5):376-80. PubMed ID: 3994067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro induction of tumor-specific human lymphocyte antigen class I-restricted CD8 cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancer.
    Santin AD; Hermonat PL; Ravaggi A; Bellone S; Pecorelli S; Cannon MJ; Parham GP
    Am J Obstet Gynecol; 2000 Sep; 183(3):601-9. PubMed ID: 10992180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bio-immunotherapy for cancer in experimental studies and clinical application: current status and future challenges.
    Shen RN; Lu L; Kaiser HE; Broxmeyer HE
    In Vivo; 1994; 8(5):643-52. PubMed ID: 7727711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.